
Eli Lilly's Eczema Drug Clears Phase 3 Pediatric Hurdle, Eyes Label Expansion
Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.
LLYFDA approvalPhase 3 trial
